A Study of a New PET Scanner in People With Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Biograph Vision Quadra scanner, PET/CT.
- Who it may be relevant to
- Registry conditions: Non Small Cell Lung Carcinoma NSCLC, Head and Neck Cancer, Prostate Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Quality Improvement Study of a New Generation of Whole Body PET Scanners
Overview
The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.
Detailed description
This protocol is a quality improvement protocol intended to explore and capitalize on the advanced performance characteristics of a new total body PET scanner; the Biograph Vision Quadra manufactured by Siemens Healthineers.
Interventions
- Diagnostic test Biograph Vision Quadra scanner
new total-body PET scanner, 1 or 2 additional scans with the Biograph Vision Quadra scanner. - Diagnostic test PET/CT
Scheduled PET/CT scan
Primary outcome measures
- image quality [Time frame: 3 years]
Eligibility criteria
Inclusion criteria
Eligibility Criteria for objective #1:
- Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
- Patients who are undergoing a planned PET-CT scan at main campus of MSK.
- Patients must be ≥ 18 years old
Eligibility Criteria for objective #2:
- Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
- Patients with metastatic prostate or head and neck cancer.
- Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
- Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
- Patients must be ≥ 18 years old
Eligibility Criteria for objective #3:
- Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
- Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an \[18F\]-fluormisonidazole PET-CT scan at the main campus of MSK.
- Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
- Patients must be ≥ 18 years old
Exclusion criteria
- Patients who suffer from claustrophobia.
- Women who are pregnant or breast-feeding.
- Patients < 18 years of age
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 7 centers
- Memorial Sloan Kettering Basking Ridge (Consent Only) — Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent Only) — Middletown
- Memorial Sloan Kettering Bergen (Consent Only ) — Montvale
- Memorial Sloan Kettering Suffolk-Commack (Consent Only) — Commack
- Memorial Sloan Kettering Westchester (Consent Only) — Harrison
- Memorial Sloan Kettering Cancer Center — New York
- Memorial Sloan Kettering Nassau (Consent Only) — Rockville Centre
Identifiers
NCT: NCT07690917 · 26-227